BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II

EMBO Journal

Volumn 19, Issue 13, 2000, Pages 3314-3324

  Kirsch, Thomas ^a   Nickel, Joachim ^a   Sebald, Walter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Binding epitope; Bone morphogenetic protein; Receptor signalling; TGF superfamily

Indexed keywords

ACTIVIN RECEPTOR; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR; EPITOPE; MUTANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BINDING AFFINITY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANIMALIA; ESCHERICHIA COLI; VERTEBRATA;

EID: 0034600953     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/19.13.3314     Document Type: Article

References (54)

1. Black, J. (1989) Drugs from emasculated hormones: the principle of syntopic antagonism. Science, 245, 486-493.
2. Blessing, M., Schirmacher, P. and Kaiser, S. (1996) Overexpression of bone morphogenetic protein-6 (BMP-6) in the epidermis of transgenic mice: inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions. J. Cell Biol., 135, 227-239.
3. Chalaux, E., Lopez Rovira, T., Rosa, J.L., Bartrons, R. and Ventura, F. (1998) JunB is involved in the inhibition of myogenic differentiation by bone morphogenetic protein-2. J. Biol. Chem., 273, 537-543.
4. Chen, Y., Riese, M.J., Killinger, M.A. and Hoffmann, F.M. (1998) A genetic screen for modifiers of Drosophila decapentaplegic signaling identifies mutations in punt. Mothers against dpp and the BMP-7 homologue, 60A. Development, 125, 1759-1768.
5. Cunningham, B.C. and Wells, J.A. (1993) Comparison of a structural and a functional epitope [published erratum appears in J. Mol. Biol., 237, 513]. J. Mol. Biol., 234, 554-563.
6. Daopin, S., Piez, K.A., Ogawa, Y. and Davies, D.R. (1992) Crystal structure of transforming growth factor-β2: an unusual fold for the superfamily. Science, 257, 369-373.
7. Donaldson, C.J., Vaughan, J.M., Corrigan, A.Z., Fischer, W.H. and Vale, W.W. (1999) Activin and inhibin binding to the soluble extracellular domain of activin receptor II. Endocrinology, 140, 1760-1766.
8. Eketjall, S., Fainzilber, M., Murray Rust, J. and Ibanez, C.F. (1999) Distinct structural elements in GDNF mediate binding to GFRα1 and activation of the GFRα1-c-Ret receptor complex. EMBO J., 18, 5901-5910.
9. Gilboa, L., Nohe, A., Geissendörfer, T., Sebald, W., Henis, Y.I. and Knaus, P. (2000) BMP receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol. Biol. Cell, 11, 1023-1035.
10. Greenwald, J., Fischer, W.H., Vale, W.W. and Choe, S. (1999) Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase. Nature Struct. Biol., 6, 18-22.
11. Griffith, D.L., Keck, P.C., Sampath, T.K., Rueger, D.C. and Carlson, W.D. (1996) Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Proc. Natl Acad. Sci. USA, 93, 878-883.
12. Hammerschmidt, M., Serbedzija, G.N. and McMahon, A.P. (1996) Genetic analysis of dorsoventral pattern formation in the zebrafish: requirement of a BMP-like ventralizing activity and its dorsal repressor. Genes Dev., 10, 2452-2461.
13. Heldin, C.H. (1995) Dimerization of cell surface receptors in signal transduction. Cell, 80, 213-223.
14. Heldin, C.H., Miyazono, K. and ten Dijke, P. (1997) TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature, 390, 465-471.
15. Hogan, B.L. (1996) Bone morphogenetic proteins in development. Curr. Opin. Genet. Dev., 6, 432-438.
16. Huang, S.S., Zhou, M., Johnson, F.E., Shieh, H.S. and Huang, J.S. (1999) An active site of transforming growth factor-β1 for growth inhibition and stimulation. J. Biol. Chem., 274, 27754-27758.
17. Ide, H., Katoh, M., Sasaki H., Yoshida, T., Aoki, K., Nawa, Y., Osada, Y., Sugimura, T. and Terada, M. (1997) Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs [published erratum appears in Oncogene, 15, 1121]. Oncogene, 14, 1377-1382.
18. Iemura, S., Yamamoto, T.S., Takagi, C., Uchiyama, H., Natsume, T., Shimasaki, S., Sugino, H. and Ueno, N. (1998) Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc. Natl Acad. Sci. USA, 95, 9337-9342.
19. Katagiri, T. et al. (1994) Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage [published erratum appears in J. Cell Biol., 128, following 713]. J. Cell Biol., 127, 1755-1766.
20. Kawabata, M., Chytil, A. and Moses, H.L. (1995) Cloning of a novel type II serine/threonine kinase receptor through interaction with the type I transforming growth factor-β receptor. J. Biol. Chem., 270, 5625-5630.
21. Kirsch, T., Nickel, J. and Sebald, W. (2000) Isolation of recombinant BMP receptor IA ectodomain and its 2:1 complex with BMP-2. FEBS Lett., 468, 215-219.
22. Kirsch, T., Sebald, W. and Dreyer, M. (2000b) Crystal structure of the BMP-2-BRIA ectodomain complex. Nature Struct. Biol., 7, 492-496.
23. Koenig, B.B. et al. (1994) Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol. Cell. Biol., 14, 5961-5974.
24. Kurita, T., Matsumoto, T., Kikuno, R., Otawara-Hamamoto, Y. and Breipohl, G. (1995) Dimeric bone morphogenetic proteins and fragments and analogs thereof and pharmaceutical compositions comprising them. European Patent Application, 0691 349 A2.
25. Lawrence, D.A. (1996) Transforming growth factor-β: a general review. Eur. Cytokine Network, 7, 363-374.
26. Liu, F., Ventura, F., Doody, J. and Massague, J. (1995) Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol. Cell. Biol., 15, 3479-3486.
27. Luo, K. and Lodish, H.F. (1996) Signaling by chimeric erythropoietin-TGF-β receptors: homodimerization of the cytoplasmic domain of the type I TGF-β receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction. EMBO J., 15, 4485-4496.
28. Luo, K. and Lodish, H.F. (1997) Positive and negative regulation of type II TGF-β receptor signal transduction by autophosphorylation on multiple serine residues. EMBO J., 16, 1970-1981.
29. Macias-Silva, M., Hoodless, P.A., Tang, S.J., Buchwald, M. and Wrana, J.L. (1998) Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J. Biol. Chem., 273, 25628-25636.
30. Massague, J. (1998) TGF-β signal transduction. Annu. Rev. Biochem., 67, 753-791.
31. Matzuk, M.M. and Bradley, A. (1992) Cloning of the human activin receptor cDNA reveals high evolutionary conservation [published erratum appears in Biochim. Biophys. Acta, 1131, 243]. Biochim. Biophys. Acta, 1130, 105-108.
32. Matzuk, M.M., Kumar, T.R., Vassalli, A., Bickenbach, J.R., Roop, D.R., Jaenisch, R. and Bradley, A. (1995) Functional analysis of activins during mammalian development. Nature, 374, 354-356.
33. McPherron, A.C., Lawler, A.M. and Lee, S.J. (1997) Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature, 387, 83-90.
34. Mittl, P.R., Priestle, J.P., Cox, D.A., McMaster, G., Cerletti, N. and Grutter, M.G. (1996) The crystal structure of TGF-β 3 and comparison to TGF-β 2: implications for receptor binding. Protein Sci., 5, 1261-1271.
35. Namiki, M., Akiyama, S., Katagiri, T., Suzuki, A., Ueno, N., Yamaji, N., Rosen, V., Wozney, J.M. and Suda, T. (1997) A kinase domain-truncated type I receptor blocks bone morphogenetic protein-2-induced signal transduction in C2C12 myoblasts. J. Biol. Chem., 272, 22046-22052.
36. Nishimura, R., Kato, Y., Chen, D., Harris, S.E., Mundy, G.R. and Yoneda, T. (1998) Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J. Biol. Chem., 273, 1872-1879.
37. Nishitoh, H., Ichijo, H., Kimura, M., Matsumoto, T., Makishima, F., Yamaguchi, A., Yamashita, H., Enomoto, S. and Miyazono, K. (1996) Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J. Biol. Chem., 271, 21345-21352.
38. Nohno, T., Ishikawa, T., Saito, T., Hosokawa, K., Noji, S., Wolsing, D.H. and Rosenbaum, J.S. (1995) Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors. J Biol. Chem., 270, 22522-22526.
39. Northrup, S.H. and Erickson, H.P. (1992) Kinetics of protein-protein association explained by Brownian dynamics computer simulation. Proc. Natl Acad. Sci. USA. 89, 3338-3342.
40. Reddi, A.H. (1994) Bone and cartilage differentiation. Curr. Opin. Genet. Dev., 4, 737-744.
41. Reddi, A.H. (1997) Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev., 8, 11-20.
42. Reddi, A.H. (1998) Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nature Biotechnol., 16, 247-252.
43. Rosenzweig, B.L., Imamura, T., Okadome, T., Cox, G.N., Yamashita, H., ten Dijke, P., Heldin, C.H. and Miyazono, K. (1995) Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl Acad. Sci. USA, 92, 7632-7636.
44. Ruppert, R., Hoffmann, E. and Sebald, W. (1996) Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur. J. Biochem., 237, 295-302.
45. Scheufler, C., Sebald, W. and Hulsmeyer, M. (1999) Crystal structure of human bone morphogenetic protein-2 at 2.7 Å resolution. J. Mol. Biol., 287, 103-115.
46. Schlunegger, M.P. and Grutter, M.G. (1992) An unusual feature revealed by the crystal structure at 2.2 Å resolution of human transforming growth factor-β2. Nature, 358, 430-434.
47. Shen, B.J., Hage, T. and Sebald, W. (1996) Global and local determinants for the kinetics of interleukin-4/interleukin-4 receptor α chain interaction. A biosensor study employing recombinant interleukin-4-binding protein. Eur. J. Biochem., 240, 252-261.
48. ten Dijke, P., Yamashita, H., Ichijo, H., Franzen, P., Laiho, M., Miyazono, K. and Heldin, C.H. (1994a) Characterization of type I receptors for transforming growth factor-β and activin. Science, 264, 101-104.
49. ten Dijke, P., Yamashita, H., Sampath, T.K., Reddi, A.H., Estevez, M., Riddle, D.L., Ichijo, H., Heldin, C.H. and Miyazono, K. (1994b) Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J. Biol. Chem., 269, 16985-16988.
50. Weis Garcia, F. and Massague, J. (1996) Complementation between kinase-defective and activation-defective TGF-β receptors reveals a novel form of receptor cooperatively essential for signaling. EMBO J., 15, 276-289.
51. Wozney, J.M., Rosen, V., Celeste, A.J., Mitsock, L.M., Whitters, M.J., Kriz, R.W., Hewick, R.M. and Wang, E.A. (1988) Novel regulators of bone formation: molecular clones and activities. Science, 242, 1528-1534.
52. Wrana, J.L., Attisano, L., Wieser, R., Ventura, F. and Massague, J. (1994) Mechanism of activation of the TGF-β receptor. Nature, 370, 341-347.
53. Wuytens, G. et al. (1999) Identification of two amino acids in activin A that are important for biological activity and binding to the activin type II receptors. J. Biol. Chem., 274, 9821-9827.
54. Yamashita, H., ten Dijke, P., Huylebroeck, D., Sampath, T.K., Andries, M., Smith, J.C., Heldin, C.H. and Miyazono, K. (1995) Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J. Cell Biol., 130, 217-226.